Deep Vein Thrombosis  
The MD Magazine Deep Vein Thrombosis condition center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.


Rivaroxaban Approval Sought for Recurrent VTE Risk Reduction
A supplemental new drug application has been submitted to the US Food and Drug Administration (FDA) for 10-mg rivaroxaban as a treatment to reduce the risk of recurrent venous thromboembolism (VTE) after at least six months of standard anticoagulation therapy.
Compared with warfarin, are direct oral anticoagulants (DOACs), including apixaban, dabigatran, and rivaroxaban, better at reducing stroke and major bleeding risks in patients with non-valvular atrial fibrillation? Alpesh Amin, MD, professor of medicine at the University of California, Irvine breaks it down at ACC 2017 in Washington, District of Columbia.
Heart damage after non-cardiac surgery is usually missed. A test finds it.
Paul Burton, MD, PhD, revealed results from the phase 3 EINSTEIN CHOICE trial at the 66th Scientific Session of the American College of Cardiology (ACC 2017) in Washington, District of Columbia. The trial examined the use of rivaroxaban (Xarelto/Janssen) or aspirin as extended treatment in patients with VTE.
Several studies have shown that patients with sleep apnea are more likely than others to develop atrial fibrillation, but recent information indicates that any type of disrupted sleep may indicate an elevated risk.
It is reportedly safe to use tissue plasminogen activator, the clot busting medication, on patients who wake up with symptoms of stroke, according to a new study. Generally, tPA should be administered within 4.5 hours of symptom onset to be considered effective.
Authors of a new meta-analysis of warfarin use in ESRD patients raised concerns that the anticoagulant may not lower stroke risk in these patients, and as such, might itself be an unnecessary risk.
“We found that the risk of ischemic stroke...the most common stroke subtype, is increased in overweight and obese women,” study author Gillian Reeves, explained. “By contrast, the risk of hemorrhagic decreased in overweight and obese women.
A large registry study has found that short bouts of atrial fibrillation (AF) are not associated with any adverse events and, therefore, may not require anticoagulation or any other treatment.

Most Popular


$vacMongoViewPlus$ $vAR$